About the study

This is a Phase I/II study designed to evaluate if experimental anti-TIGIT/anti-PD-1 bispecific antibody, AZD2936 is safe, tolerable and efficacious in participants with Advanced or Metastatic Non-small Cell Lung Cancer.

Who can take part?

You may be eligible to participate in the study if you meet the following criteria:

Inclusion criteria

1. Written informed consent
2. Aged 18 or above
3. Part A and Part B: Unresectable stage III or stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation. Part C and Part D: Stage IV squamous or non-squamous NSCLC not amenable to curative surgery or radiation.
4. Documented PD-L1 expression by PD-L1 IHC per local report.
5. Part A and Part B: Confirmed progression during treatment with a CPI-including regimen.
6. Part C and Part D: No prior I/O treatment for NSCLC.
7. ECOG performance status of 0 or 1 at enrolment.
8. Life expectancy of ≥ 12 weeks at enrolment.
9. Have at least 1 measurable lesion per RECIST v1.1.
10. Adequate bone marrow, liver and kidney function

Exclusion criteria

1. Sensitizing epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) fusion
2. Documented test result for any other known genomic alteration for which a targeted therapy is approved in first line per local standard of care (e.g. ROS1, NTRK fusions, BRAF, V600E mutation)
3. Previous treatment with an anti-TIGIT therapy
4. Any concurrent chemotherapy, radiotherapy, investigational, biologic, or hormonal therapy for cancer treatment.
5. Part A and Part B: Primary or secondary resistance after treatment with 2 or more regiments including a CPI.
6. Part C and Part D: Any prior systemic treatment with an immune-oncology agent (Treatment with one previous systemic chemotherapy will be allowed).
7. Primary or secondary resistance after treatment with 2 or more regimens including a CPI.
8. Symptomatic central nervous system (CNS) metastasis.
9. Thromboembolic event within 3 months prior to enrolment.
10. Other invasive malignancy within 2 years prior to screening.

For a full list of inclusion/exclusion criteria, please visit ClinicalTrials.gov

Study locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to apply

Determine if a study site for this clinical trial is near you. Contact the study to apply.